Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

LYMPHIR sales more than doubled, but audited revenue and profit data remain pending.

What the company is saying

Citius Oncology, Inc. (NASDAQ:CTOR), led by CEO Leonard Mazur, reports preliminary, unaudited LYMPHIR sales data for the fiscal fourth quarter ended September 30, 2026. The company highlights a 120% quarter-over-quarter increase in units sold to U.S. wholesalers, attributing this to expanded commercial coverage achieved in August. Management emphasizes being over halfway to its goal of 100 formulary placements by year-end, with 54 institutions now ordering LYMPHIR. The announcement frames the CTCL market opportunity as exceeding $400 million and describes the market as growing and underserved. The company underscores robust intellectual property protections and ongoing efforts to deepen institutional penetration and sales growth. All figures are explicitly labeled as preliminary and unaudited, with final audited results expected in December 2026.

What the data suggests

The reported 792 LYMPHIR units sold to U.S. wholesalers in Q4 2026 represent a 120% increase from 360 units in Q3, indicating strong sequential growth. Prescribing centers ordered 950 vials in Q4, up from 926 in Q3, showing modest but positive momentum in end-user demand. The number of institutions ordering LYMPHIR rose from 44 in August to 54 by late October, reflecting progress toward the 100-institution formulary target. Management's estimate of a $400 million initial CTCL market is not independently substantiated in the release. All sales and order data are unaudited and may change after year-end closing and audit. Revenue is recognized only on wholesaler sales, not on institutional orders, so actual realized revenue will depend on gross-to-net adjustments and final audit outcomes. No profit, margin, or cash flow figures are disclosed, and the ultimate financial impact remains unquantified until audited results are published.

Analysis

The announcement presents a positive tone, highlighting a 120% quarter-over-quarter increase in preliminary LYMPHIR unit sales and expanding institutional adoption. These realised sales figures are concrete, but they are unaudited and revenue/profitability metrics are not disclosed, limiting the strength of the signal. Several claims—such as the $400 million market size, future formulary goals, and ongoing FDA engagement—are forward-looking or based on management estimates without external validation. The language around market opportunity and competitive positioning is promotional, but the core sales growth is supported by disclosed numbers. There is no indication of a large new capital outlay or long-dated, uncertain returns in this update. The gap between narrative and evidence is moderate: realised sales growth is clear, but the broader commercial and financial impact remains to be substantiated with audited results.

Risk flags

• ●All sales and order numbers are preliminary and unaudited, so actual results may differ after year-end closing and audit, introducing uncertainty about the true financial impact.
• ●The company’s revenue recognition is based on wholesaler sales, but gross-to-net adjustments and final realized revenue are not disclosed, making it unclear how much topline growth will translate into profit.
• ●Management’s $400 million CTCL market estimate is not supported by external data or detailed growth rates, so the addressable market size and potential for further penetration are uncertain.
• ●The company is still short of its 100-institution formulary goal, and future adoption rates may slow as initial momentum fades or as it encounters more challenging institutional barriers.
• ●There is ongoing reliance on robust intellectual property claims and pending patents, but no specifics on patent status, expiry, or competitive threats are provided, leaving IP durability unquantified.

Bottom line

Citius Oncology’s preliminary Q4 figures show strong growth in LYMPHIR sales and expanding institutional adoption, with wholesaler units up 120% sequentially and 54 institutions now ordering. The company is making tangible progress toward its formulary target, but all numbers are unaudited and subject to revision, and no actual revenue or profit figures are disclosed. Management’s $400 million market estimate and claims of robust IP protections are not independently verified in this release. Investors will need to see December’s audited results to assess whether sales momentum translates into meaningful revenue and margin gains. The key takeaway is that commercial traction is improving, but the scale and profitability of this growth remain unproven until the audit is complete.

Announcement summary

(NASDAQ:CTOR) Citius Oncology, Inc., an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), announced preliminary, unaudited LYMPHIR (denileukin diftitox-cxdl) unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026. For the three months ended September 30, 2026, U.S. wholesalers purchased 792 units of LYMPHIR, compared to 360 units for the three months ended June 30, 2026, representing an increase of 120%. Prescribing centers ordered 950 LYMPHIR vials from wholesalers during the fiscal fourth quarter, compared to 926 in the fiscal third quarter. As of the date of the release, 54 institutions have ordered LYMPHIR, up from 44 as of August 14, 2026. The company’s expanded commercial team achieved nationwide coverage in August 2026. Citius Oncology is more than halfway to its goal of having LYMPHIR on formulary at 100 priority institutions by calendar year-end. The company recognizes revenue when wholesaler orders are fulfilled, with revenue based on LYMPHIR units sold to wholesalers, net of estimated gross-to-net adjustments. The unit information is preliminary and unaudited, based on management's current estimates, and subject to completion of year-end closing procedures and audit of fiscal 2026 financial statements. The company expects to report complete fiscal fourth quarter and fiscal year 2026 results in December 2026 with the filing of its Annual Report on Form 10-K. LYMPHIR is a targeted immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I–III disease after at least one prior systemic therapy, and was approved by the FDA and launched in the U.S. in December 2025. Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Citius Oncology holds robust intellectual property protections for LYMPHIR, including orphan drug designation, complex technology, trade secrets, and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors. Citius Pharmaceuticals, Inc. is the majority owner of Citius Oncology and has a late-stage pipeline including Mino-Lok (a catheter lock solution) and CITI-002 (Halo-Lido, a topical formulation for hemorrhoids). A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023, with Mino-Lok meeting primary and secondary endpoints. Citius Pharma is actively engaged with the FDA to outline next steps for both programs.

Disagree with this article?